TELEX HEBDOMADAIRE NR 95 DU 17.09.82 DESTINE A L'ENSEMBLE DES DELEGATIONS EXTERIEURES ET BUREAUX DE PRESS ET D'INFORMATION INDEPENDANTS DANS LES PAYS TIERS = WEEKLY MEMO NO. 95 FOR 17.09.82 TO FOREIGN DELEGATIONS AND PRESS BUREAUS OF THIRD COUNTRIES

<p>High-performance liquid chromatography (HPLC) results of (A) commercial surfactin sample, and (B) our extract surfactin of <i>B</i>. <i>subtilis</i> HH2 in LB medium. There were three main peaks (Peak A-C) of the extract and the surfactin standard in the same location.</p

Differential Expression of Phospholipase C Epsilon 1 Is Associated with Chronic Atrophic Gastritis and Gastric Cancer

<div><h3>Background</h3><p>Chronic inflammation plays a causal role in gastric tumor initiation. The identification of predictive biomarkers from gastric inflammation to tumorigenesis will help us to distinguish gastric cancer from atrophic gastritis and establish the diagnosis of early-stage gastric cancer. Phospholipase C epsilon 1 (PLCε1) is reported to play a vital role in inflammation and tumorigenesis. This study was aimed to investigate the clinical significance of PLCε1 in the initiation and progression of gastric cancer.</p> <h3>Methodology/Principal Findings</h3><p>Firstly, the mRNA and protein expression of PLCε1 were analyzed by reverse transcription-PCR and Western blotting in normal gastric mucous epithelial cell line GES-1 and gastric cancer cell lines AGS, SGC7901, and MGC803. The results showed both mRNA and protein levels of PLCε1 were up-regulated in gastric cancer cells compared with normal gastric mucous epithelial cells. Secondly, this result was confirmed by immunohistochemical detection in a tissue microarray including 74 paired gastric cancer and adjacent normal tissues. Thirdly, an independence immunohistochemical analysis of 799 chronic atrophic gastritis tissue specimens demonstrated that PLCε1 expression in atrophic gastritis tissues were down-regulated since PLCε1 expression was negative in 524 (65.6%) atrophic gastritis. In addition, matched clinical tissues from atrophic severe gastritis and gastric cancer patients were used to further confirm the previous results by analyzing mRNA and protein levels expression of PLCε1 in clinical samples.</p> <h3>Conclusions/Significances</h3><p>Our results suggested that PLCε1 protein may be a potential biomarker to distinguish gastric cancer from inflammation lesion, and could have great potential in applications such as diagnosis and pre-warning of early-stage gastric cancer.</p> </div

The expression of PLCε1 protein in gastric cancer, normal and atrophic gastritis patients.

<p>The expression of PLCε1 protein in gastric cancer, normal and atrophic gastritis patients.</p

The expression of PLCε1 protein in gastric cancer tissue and adjacent normal tissue.

<p>The expression of PLCε1 protein in gastric cancer tissue and adjacent normal tissue.</p

Expression analysis of PLCε1 protein and mRNA in gastric normal and cancer cell lines.

<p>A, expression of PLCε1 mRNA in gastric normal cell line GES-1and cancer cell lines SGC7901, MGC803 and AGS by reverse transcription-PCR. B, expression of PLCε1 protein gastric normal cell lines GES-1 and cancer cell lines SGC7901, MGC803 and AGS by Western blotting.</p

PLCε1 is positively expressed in lymphocytes in normal and atrophic gastritis tissues, respectively.

<p>Representative immunohistochemical (A)/histological (B) observations in a gastric normal tissue, Representative immunohistochemical (C)/histological (D) observations in a atrophic gastritis tissue. Arrows indicate positively stained immune cells (Original magnification, ×200).</p

Immunohistochemical detection of PLCε1 protein in gastric cancer and atrophic gastritis patients.

<p>Representative images from Immunohistochemical analysis of 74 archived gastric cancer and 799 atrophic gastritis cases. A, overview of the tissue microarray by immunostaining of antibody PLCε1. Boxed biopsies are shown in detail in (B and C). B and C are matched tumor and adjacent normal tissues from same patient. The patient is pTNM stage III with poorly differentiated adenocarcinoma. Both tumor (B) and adjacent normal (C) cells are positive for PLCε1. Representative immunohistochemical (D)/histological (G) observations in a atrophic gastritis tissue, Representative immunohistochemical (E)/histological (H)observations in a gastric normal tissue, Representative immunohistochemical (F)/histological (I) observations in a gastric cancer tissue. (Original magnification, ×2 for B and C, ×200 for D, E, F, G, H and I).</p

Expression analysis of PLCε1 mRNA and protein in gastric cancer and atrophic gastritis patients.

<p>A and C, expression of PLCε1 mRNA and protein in each of the gastric tumors (T) and gastric adjacent normal tissues (N) paired from the same patient by reverse transcription-PCR and western blot. B and D, expression of PLCε1mRNA and protein in each of the severe atrophic gastritis (S) and gastric adjacent normal tissues (N) paired from the same patient by reverse transcription-PCR and Western blotting.</p

Characterization of 16 specimens based on multi-locus sequences of <i>bg</i>, <i>tpi</i> and <i>gdh</i> genes.

<p>Characterization of 16 specimens based on multi-locus sequences of <i>bg</i>, <i>tpi</i> and <i>gdh</i> genes.</p

Table_1_Phage P2-71 against multi-drug resistant Proteus mirabilis: isolation, characterization, and non-antibiotic antimicrobial potential.docx

Proteus mirabilis, a prevalent urinary tract pathogen and formidable biofilm producer, especially in Catheter-Associated Urinary Tract Infection, has seen a worrying rise in multidrug-resistant (MDR) strains. This upsurge calls for innovative approaches in infection control, beyond traditional antibiotics. Our research introduces bacteriophage (phage) therapy as a novel non-antibiotic strategy to combat these drug-resistant infections. We isolated P2-71, a lytic phage derived from canine feces, demonstrating potent activity against MDR P. mirabilis strains. P2-71 showcases a notably brief 10-minute latent period and a significant burst size of 228 particles per infected bacterium, ensuring rapid bacterial clearance. The phage maintains stability over a broad temperature range of 30-50°C and within a pH spectrum of 4-11, highlighting its resilience in various environmental conditions. Our host range assessment solidifies its potential against diverse MDR P. mirabilis strains. Through killing curve analysis, P2-71’s effectiveness was validated at various MOI levels against P. mirabilis 37, highlighting its versatility. We extended our research to examine P2-71’s stability and bactericidal kinetics in artificial urine, affirming its potential for clinical application. A detailed genomic analysis reveals P2-71’s complex genetic makeup, including genes essential for morphogenesis, lysis, and DNA modification, which are crucial for its therapeutic action. This study not only furthers the understanding of phage therapy as a promising non-antibiotic antimicrobial but also underscores its critical role in combating emerging MDR infections in both veterinary and public health contexts.</p